Empagliflozin attenuates ISO-induced myocardial injury through PGC-1α-mediated mitochondrial biogenesis and improved fatty acid metabolism

Empagliflozin attenuates ISO-induced myocardial injury through PGC-1α-mediated mitochondrial biogenesis and improved fatty acid metabolism. Download PDF Abstract Empagliflozin, as a sodium-glucose cotransporter 2 inhibitor (SGLT2i), has demonstrated beneficial cardioprotective effects in patients with heart failure. The cardiac benefits of empagliflozin are not entirely dependent on the classical SGLT2 receptor-mediated mechanism and may also be associated with the improvement of cardiomyocyte mitochondrial function and fatty acid metabolism.

This study aimed to evaluate the effects of empagliflozin on cardiac function and elucidate its potential targets and underlying mechanisms. Rats with ISO-induced myocardial injury were later treated with empagliflozin by intragastric administration. Compared with the model group, empagliflozin improved cardiac function and alleviated pathological changes, including myocardial hypertrophy and fibrosis.

Empagliflozin significantly reduced the expression levels of cytochrome c (Cyt c), Bax, and cleaved-caspase-3, increased Bcl-2 expression, attenuated cardiomyocyte apoptosis, and decreased serum levels of BNP, sST2, and cTnT. Empagliflozin preserved mitochondrial morphology and cristae structure, reduced myocardial ROS levels, significantly increased mitochondrial membrane potential and mtDNA copy number, and upregulated the expression of PGC-1α, NRF1, NRF2, and TFAM. Following empagliflozin intervention, the expression levels of PPARα, CPT1, CPT2, and MCAD were increased, promoting fatty acid utilization in myocardial tissue and enhancing ATP production.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with qualified healthcare professionals for medical decisions and treatment options.